

## **PCT**

## INTERNATIONALSEARCHREPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference  JA504705	FOR FURTHER see Notification of ACTION (Form PCT/ISA/2	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.					
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)					
PCT/JP03/07333	10.06.03	10.06.02					
Applicant THE UNIVERSITY OF EDINBURGH							
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.  This international search report consists of a total of4 sheets.							
It is also accompanied by a copy of each prior art document cited in this report.							
language in which it was filed, u  the international search wa  Authority (Rule 23.1(b)).	ne international search was carried out on the inless otherwise indicated under this item.  as carried out on the basis of a translation of the internation acid sequence disclosed in the internation.	the international application furnished to this					
<ul> <li>b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:</li> <li>contained in the international application in written form.</li> <li>filed together with the international application in computer readable form.</li> </ul>							
furnished subsequently to this Authority in written form.							
	furnished subsequently to this Authority in computer readable form.						
the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.							
the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.							
	nd unsearchable (See Box I).						
3. Unity of invention is lacking (See Box II).							
4. With regard to the title,							
the text is approved as submitted by the applicant.							
the text has been establish	ed by this Authority to read as follows:						
5 Wish regard to the obstroot	••						
5. With regard to the abstract, the text is approved as sub-	imitted by the applicant						
the text has been establish	ed, according to Rule 38.2(b), by this Authori e date of mailing of this international search 1	ty as it appears in Box III. The applicant may, report, submit comments to this Authority.					
6. The figure of the drawings to be p	ublished with the abstract is Figure No.						
as suggested by the applic	·	None of the figures.					
because the applicant faile							
	characterizes the invention.						

			PCI/UPU.	3,01333
A. CLAS	SSIFICATION OF SUBJECT MATTER 07K7/06,A61K38/08,A61K38/55,A61P1,	/04,A61P1/14,	A61P27/02,A61	LP43/00
According to	International Patent Classification (IPC) or to both na	ational classification a	nd IPC	· 
	OS SEARCHED .			
Minimum documentation searched (classification system followed by classification symbols) Int.Cl <sup>2</sup> C07K7/06, A61K38/08, A61K38/55, A61P1/04, A61P1/14, A61P27/02, A61P43/00				
Japanese Applicat Containi	on searched other than minimum documentation to the ext Utility Model Gazette 1926-1996, Japane ions 1971-2001, Japanese Registered Util ng the Utility Model 1996-2001	ity Model Gazette	1994-2001,	Japanese Gazette
Electronic da	ta base consulted during the international search (name of	data base and, where pr	acticable, search tern	ns used)
BIOSIS	(DIALOG), WPI (DIALOG), REGISTRY (STN	),CA(STN)		_
C. DOCUM	MENTS CONSIDERED TO BE RELEVANT			
Category*	Citation of document, with indication, where ap	propriate, of the relev	ant passages	Relevant to claim No.
Y	WO 01/62291 A1(FUSO PHARM &JP 2001-233790 A &AU 2001	IND LTD) 20 32345 A	01.08.30	1-7
	&EP 1258251 A1			<u>.</u>
<b>.</b>	Y WO 01/47556 A1(FUSO PHARM IND LTD)2001.07.05 & JP 2001-181208 A &AU 200117342 A &EP 1247532 A1			
Y	Maryanoff BE et al, Protease-activated 1-7 receptor-2 (PAR-2): structure-function study of receptor activation by diverse peptides related to tethered-ligand epitopes.,  Arch Biochem Biophys.,			
2001, Vol. 386, No. 2, p. 195-204.  y Santagada V et al, Minimal structural requirements for agonist activity of PAR-2 activating peptides. , Bioorg Med Chem Lett. , 2002 Jan , Vol. 12, No. 1, p. 21-4.			1-7	
				·
Further documents are listed in the continuation of Box C. See patent family annex.				
* Special categories of cited documents:  "A" document defining the general state of the art which is not considered to be of particular relevance  "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention				
"E" earlier application or patent but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone				
cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "O" document referring to an oral disclosure, use, exhibition or other means				
"P" document published prior to the international filing date but later than "&" document member of the same patent family the priority date claimed				
Date of the a	actual completion of the international search 22.07.03	Date of mailing of th	05.08.0	
Name and mailing address of the ISA/JP. Authorized officer 4B 9735				
	Japan Patent Office	Noriko Mu	ıkasa	Seal 4B 3733



C (Continuati	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Category* Y	D'Alessio S et al, Inhibition of adamalysin II and MMPs by phosphonate analogues of snake venom peptides., Bioorg Med Chem., 1999, Vol. 7, No. 2, p. 389-94.	1-7
Υ	WO 97/25351 A2 (MILLENNIUM PHARM INC) 1997.07.17 &AU 9722415 A &EP 871670 A2 &US 6037324 A &JP 2000-503203 A &AU 721615 B &US 6274556 B1 &US 2002/0103111 A1	1-7
P, A	WO 02/56916 A2 (ZIMMER R H) 2002.07.25 &US 2002/0132777 A1	1-7
	·	



Claim 1-7 is not supported by the description as required by Article 6 PCT. The reason therefor is the following: aryl group in claim 1 contains a lot of structure, but in the description, only a few structures are disclosed.

We searched the subject matter of claim 1-7 which is supported by the description, Z -(CH2)n represents in the example 1-18,AA1-AA2 represents Lys-Val or Arg-Leu,and R represents -OH or -NH2.